CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Clinical trials for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION explained in plain language.
Never miss a new study
Get alerted when new CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION trials appear
Sign up with your email to follow new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Smartphone app may help heart failure patients get the right meds faster
Disease control CompletedThis study tested whether using a smartphone app and phone calls to monitor patients after a heart failure hospital stay helps doctors safely increase their medications. 66 adults with chronic heart failure and low ejection fraction were split into two groups: one received usual …
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: NA • Sponsor: I.M. Sechenov First Moscow State Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New heart failure drug tested in 2,400 chinese patients
Disease control CompletedThis study collected data from 2,400 adults in China with chronic heart failure to see how well the drug vericiguat works compared to standard treatments. Researchers tracked deaths, hospital stays, and side effects over 12 months. The goal is to understand if vericiguat helps co…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Heart failure pill aims to cut deaths and hospital visits
Disease control CompletedThis large phase 3 trial tested the drug vericiguat in over 6,000 adults with chronic heart failure and a weakened heart pump. Participants took a daily pill or a placebo to see if the drug could lower the chance of dying from heart problems or being hospitalized for heart failur…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a higher starting dose of vericiguat speed up heart failure treatment?
Disease control CompletedThis study tested whether starting the heart failure drug vericiguat at a 5 mg dose (instead of the usual 2.5 mg) is safe and tolerable. 106 adults with chronic heart failure with reduced ejection fraction took the 5 mg tablet daily for about two weeks. The goal was to see if ski…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Heart failure drug vericiguat put to the test in everyday care
Disease control CompletedThis study looked at data from 500 people in Germany who started taking vericiguat for chronic heart failure with reduced ejection fraction. Researchers wanted to see how well the drug works outside of clinical trials, in routine medical care. They tracked deaths and hospitalizat…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Disease control
Last updated Jun 26, 2026 15:37 UTC
-
Heart failure drug vericiguat under Real-World scrutiny in japan
Knowledge-focused CompletedThis study analyzed data from nearly 5,000 Japanese patients with chronic heart failure who started taking vericiguat as part of their regular care. Researchers tracked outcomes like hospital stays and deaths over one year to see how the drug performs in everyday practice. The go…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC